Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium

Maturitas

Volumn 28, Issue 1, 1997, Pages 83-88

  Ross, D ^a   Godfree, V ^b   Cooper, A ^a   Pryse Davies, J ^c   Whitehead, M I ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Amarant Centre   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Orally active progestogen; Postmenopausal endometrium; Trimegestrone

Indexed keywords

ESTRADIOL; PROGESTERONE DERIVATIVE; PROMEGESTONE; TRIMEGESTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; PROMEGESTONE; PROSPECTIVE STUDIES;

EID: 0030699191     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00058-3     Document Type: Article

References (15)

1. Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978;1:87-98.
2. Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
4. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen/progestagen replacement. Br J Obstet Gynaecol 1992;99:821-8.
5. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
6. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovasular disease. N Engl J Med 1996;335:453-61.
7. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system, Nonlipid effects. Drugs 1994;47 Suppl 2:35-41.
8. Burch DJ, Spowart KJM, Jesinger DK, Randall S. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17-β-oestradiol. Br J Obstet Gynaecol 1995;102:243-8.
9. van der Mooren MJ, Demacker PN, Thomas CM, Borm GF, Rolland R. A 2-year study on the beneficial effects of 17-β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993;52:117-23.
10. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298-304.
11. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950;1:3-25.
12. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New Engl J Med 1981;305:1599-605.
13. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 1983;287:1241-5.
14. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
15. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83: 686-94.